Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phenter-mine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.

Telci Caklili, O., Cesur, M., Mikhailidis, D.P., Rizzo, M. (2023). Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview. DIABETES, METABOLIC SYNDROME AND OBESITY, 16, 1767-1774 [10.2147/DMSO.S392684].

Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview

Rizzo, Manfredi
2023-01-01

Abstract

Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phenter-mine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.
2023
Telci Caklili, O., Cesur, M., Mikhailidis, D.P., Rizzo, M. (2023). Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview. DIABETES, METABOLIC SYNDROME AND OBESITY, 16, 1767-1774 [10.2147/DMSO.S392684].
File in questo prodotto:
File Dimensione Formato  
2023 Diabetes, Metabolic Syndrome and Obesity.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 524.66 kB
Formato Adobe PDF
524.66 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/620493
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 2
social impact